Cargando…

The (18)F-FDG PET/CT response to radiotherapy for patients with spinal metastasis correlated with the clinical outcomes

PURPOSE: To evaluate the potential role of (18)F-fluorodeoxyglucose-positron emission tomography/computerized tomography (FDG-PET/CT) for predicting treatment response after radiotherapy (RT) in patients with spinal metastases. MATERIALS AND METHODS: A retrospective analysis was performed of 42 pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Jinhyun, Kim, Jun Won, Jeon, Tae Joo, Lee, Ik Jae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161908/
https://www.ncbi.nlm.nih.gov/pubmed/30265736
http://dx.doi.org/10.1371/journal.pone.0204918
_version_ 1783359073814577152
author Choi, Jinhyun
Kim, Jun Won
Jeon, Tae Joo
Lee, Ik Jae
author_facet Choi, Jinhyun
Kim, Jun Won
Jeon, Tae Joo
Lee, Ik Jae
author_sort Choi, Jinhyun
collection PubMed
description PURPOSE: To evaluate the potential role of (18)F-fluorodeoxyglucose-positron emission tomography/computerized tomography (FDG-PET/CT) for predicting treatment response after radiotherapy (RT) in patients with spinal metastases. MATERIALS AND METHODS: A retrospective analysis was performed of 42 patients with spinal metastases who received RT from January 2010 to December 2014. All patients underwent FDG-PET/CT before and after treatment. Changes in metabolic responses, expressed as the maximum, mean, peak standardized uptake values (SUVmax, SUVmean, SUVpeak), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were analyzed to determine their association with clinical outcomes. RESULTS: The median age at the time of spinal metastasis diagnosis was 58 years. Median progression-free survival (PFS) and overall survival after RT were 15 months and 22.4 months, respectively. RT produced a significant decrease in SUVmean (2.27 to 1.41), SUVmax (6.87 to 2.99), SUVpeak (5.75 to 2.33) and TLG (52.84 to 24.17) when compared with the baseline values (p<0.001). The mean pain score decreased from 3.86 before RT to 0.79 after RT (p<0.001). There were significant linear relationships between maximum SUV and pain scores at baseline (r = 0.321, p = 0.038) and after treatment (r = 0.369, p = 0.016) as well as TLG at baseline (r = 0.428, p = 0.005) and after treatment (r = 0.403, p = 0.009). Local progression after treatment was identified in 12 patients (28.6%). Univariate analyses showed that >70% reduction in maximum SUV after treatment was independently associated with good PFS (p = 0.036). CONCLUSIONS: RT is an effective treatment for patients with spinal metastases, and there were significant changes in PET parameters compared with baseline. The metabolic response measured by SUV and TLG changes in FDG-PET/CT correlated with the clinical outcomes, especially with shorter PFS in patients who had higher residual maximum SUV after treatment.
format Online
Article
Text
id pubmed-6161908
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-61619082018-10-19 The (18)F-FDG PET/CT response to radiotherapy for patients with spinal metastasis correlated with the clinical outcomes Choi, Jinhyun Kim, Jun Won Jeon, Tae Joo Lee, Ik Jae PLoS One Research Article PURPOSE: To evaluate the potential role of (18)F-fluorodeoxyglucose-positron emission tomography/computerized tomography (FDG-PET/CT) for predicting treatment response after radiotherapy (RT) in patients with spinal metastases. MATERIALS AND METHODS: A retrospective analysis was performed of 42 patients with spinal metastases who received RT from January 2010 to December 2014. All patients underwent FDG-PET/CT before and after treatment. Changes in metabolic responses, expressed as the maximum, mean, peak standardized uptake values (SUVmax, SUVmean, SUVpeak), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were analyzed to determine their association with clinical outcomes. RESULTS: The median age at the time of spinal metastasis diagnosis was 58 years. Median progression-free survival (PFS) and overall survival after RT were 15 months and 22.4 months, respectively. RT produced a significant decrease in SUVmean (2.27 to 1.41), SUVmax (6.87 to 2.99), SUVpeak (5.75 to 2.33) and TLG (52.84 to 24.17) when compared with the baseline values (p<0.001). The mean pain score decreased from 3.86 before RT to 0.79 after RT (p<0.001). There were significant linear relationships between maximum SUV and pain scores at baseline (r = 0.321, p = 0.038) and after treatment (r = 0.369, p = 0.016) as well as TLG at baseline (r = 0.428, p = 0.005) and after treatment (r = 0.403, p = 0.009). Local progression after treatment was identified in 12 patients (28.6%). Univariate analyses showed that >70% reduction in maximum SUV after treatment was independently associated with good PFS (p = 0.036). CONCLUSIONS: RT is an effective treatment for patients with spinal metastases, and there were significant changes in PET parameters compared with baseline. The metabolic response measured by SUV and TLG changes in FDG-PET/CT correlated with the clinical outcomes, especially with shorter PFS in patients who had higher residual maximum SUV after treatment. Public Library of Science 2018-09-28 /pmc/articles/PMC6161908/ /pubmed/30265736 http://dx.doi.org/10.1371/journal.pone.0204918 Text en © 2018 Choi et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Choi, Jinhyun
Kim, Jun Won
Jeon, Tae Joo
Lee, Ik Jae
The (18)F-FDG PET/CT response to radiotherapy for patients with spinal metastasis correlated with the clinical outcomes
title The (18)F-FDG PET/CT response to radiotherapy for patients with spinal metastasis correlated with the clinical outcomes
title_full The (18)F-FDG PET/CT response to radiotherapy for patients with spinal metastasis correlated with the clinical outcomes
title_fullStr The (18)F-FDG PET/CT response to radiotherapy for patients with spinal metastasis correlated with the clinical outcomes
title_full_unstemmed The (18)F-FDG PET/CT response to radiotherapy for patients with spinal metastasis correlated with the clinical outcomes
title_short The (18)F-FDG PET/CT response to radiotherapy for patients with spinal metastasis correlated with the clinical outcomes
title_sort (18)f-fdg pet/ct response to radiotherapy for patients with spinal metastasis correlated with the clinical outcomes
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161908/
https://www.ncbi.nlm.nih.gov/pubmed/30265736
http://dx.doi.org/10.1371/journal.pone.0204918
work_keys_str_mv AT choijinhyun the18ffdgpetctresponsetoradiotherapyforpatientswithspinalmetastasiscorrelatedwiththeclinicaloutcomes
AT kimjunwon the18ffdgpetctresponsetoradiotherapyforpatientswithspinalmetastasiscorrelatedwiththeclinicaloutcomes
AT jeontaejoo the18ffdgpetctresponsetoradiotherapyforpatientswithspinalmetastasiscorrelatedwiththeclinicaloutcomes
AT leeikjae the18ffdgpetctresponsetoradiotherapyforpatientswithspinalmetastasiscorrelatedwiththeclinicaloutcomes
AT choijinhyun 18ffdgpetctresponsetoradiotherapyforpatientswithspinalmetastasiscorrelatedwiththeclinicaloutcomes
AT kimjunwon 18ffdgpetctresponsetoradiotherapyforpatientswithspinalmetastasiscorrelatedwiththeclinicaloutcomes
AT jeontaejoo 18ffdgpetctresponsetoradiotherapyforpatientswithspinalmetastasiscorrelatedwiththeclinicaloutcomes
AT leeikjae 18ffdgpetctresponsetoradiotherapyforpatientswithspinalmetastasiscorrelatedwiththeclinicaloutcomes